TRBV20OR9-2
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neither TCR gene was found to be rearranged in acute nonlymphoid leukemia patients (0/12) or in patients with B-cell (surface immunoglobulin-positive) leukemia (0/3).
|
2955409 |
1987 |
TRBV20OR9-2
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings suggest that monoclonal proliferation of TCR gamma delta-positive granular lymphocytes (GL) can be associated with PRCA even in a patient having a small proportion of leukemia GL, which we propose to designate as 'smoldering GLL'.
|
7653209 |
1995 |
TRBV20OR9-2
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Utilizing newborn screening ('Guthrie') cards, leukemic clones have been detected retrospectively in dried blood spots using two different PCR-based approaches: (i) the amplification of patient/leukemia-specific breakpoint fusion sequences of rearranged oncogenes; and (ii) the amplification of clonal immunoglobulin heavy chain gene (IgH) or T cell receptor (TcR) gene rearrangements.
|
15061193 |
2004 |
TRBV20OR9-2
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pre-TCR signaling synergizes with TEL-JAK2 to transform immature thymocytes and initiate leukemogenesis as shown by (1) the delayed leukemia onset in Rag2-, CD3epsilon- and pTalpha-deficient mice, (2) the occurrence of recurrent chromosomal alterations in pre-TCR-deficient leukemia, and (3) the correction of delayed leukemia onset in Rag2-deficient TEL-JAK2 mice by an H-Y TCRalphabeta transgene that mimics pre-TCR signaling.
|
17192390 |
2007 |
TRBV20OR9-2
|
0.100 |
Biomarker
|
disease |
BEFREE |
Leukemia fusion gene analysis demonstrated positive EVI1 and negative IgH and TCR gene rearrangement.
|
30608452 |
2019 |
TRBV20OR9-2
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, PCR amplification of segments of rearranged TCR-beta is reliable and highly suitable for the detection of small populations of clonal T-cells in asymptomatic HTLV-I carriers who present abnormal peripheral blood lymphocytes providing an additional instrument for following up these patients with potentially higher risk of leukemia.
|
15917950 |
2005 |
TRBV20OR9-2
|
0.100 |
Biomarker
|
disease |
BEFREE |
The data suggest that adoptive immunotherapy with WT1-TCR gene-modified patient T cells should be considered for the treatment of leukemia.
|
16020516 |
2005 |
TRBV20OR9-2
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
TCR-beta chain gene rearrangement and expression in human T-cell development and in leukemia.
|
8207984 |
1994 |
TRBV20OR9-2
|
0.100 |
Biomarker
|
disease |
BEFREE |
A previously established human leukemia cell line, designated THP-6, was further characterized with respect to cell surface antigen expression and immunoglobulin(Ig) and T-cell receptor(TCR) gene status.
|
3130528 |
1988 |
TRBV20OR9-2
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings clearly limit the use of HMMR-TCR therapy to MHC- mismatched HSC transplantation, in which HLA-A2 differences can be used to restrict recognition to patient HSCs and leukemia.
|
22371883 |
2012 |
TRBV20OR9-2
|
0.100 |
Biomarker
|
disease |
BEFREE |
Southern analysis and polymerase chain reaction (PCR) were used to detect the rearranged V-D-J segment of T-cell receptor delta (TCR delta) gene from malignant cell specimens of patients with leukemia and lymphoma of T-cell lineage.
|
9209365 |
1997 |
TRBV20OR9-2
|
0.100 |
Biomarker
|
disease |
BEFREE |
Southern analysis and polymerase chain reaction (PCR) were used to detect the rearranged V-D-J segment of T-cell receptor delta (TCR delta) gene from malignant cell specimens of patients with leukemia and lymphoma of T-cell lineage.
|
8756082 |
1996 |
TRBV20OR9-2
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Ongoing, clonal immunoglobulin (IG) and cross-lineage T-cell receptor (TCR) gene rearrangements are features of B-cell precursor leukemia and commence at the pro-B-cell stage of normal B-cell lineage development.
|
25388957 |
2015 |
TRBV20OR9-2
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We have sought to address the question of clonal variation of TCR within a human T leukemia cell line, HPB-ALL.
|
3262674 |
1988 |
TRBV20OR9-2
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Several means of analyzing minimal residual disease (MRD) in leukemia involving the rearranged T cell receptor (TCR) gene have been described.
|
9111164 |
1997 |
TRBV20OR9-2
|
0.100 |
Biomarker
|
disease |
BEFREE |
One of these PCR assays was based on amplification of leukemia-specific TCR-delta gene rearrangements, while the other assay relied upon detection of the c-tal deletion.
|
8182934 |
1994 |
TRBV20OR9-2
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recently, a correlation between T-cell receptor (TCR) gene rearrangements and chromosomal aberrations has been implicated in this leukemia.
|
7510355 |
1994 |
TRBV20OR9-2
|
0.100 |
Biomarker
|
disease |
BEFREE |
Leukemia-associated monoclonal and oligoclonal TCR-BV use in patients with B-cell chronic lymphocytic leukemia.
|
12393705 |
2003 |
TRBV20OR9-2
|
0.100 |
Biomarker
|
disease |
BEFREE |
In a longitudinal study of a 32-year-old male with Ph1+ hybrid leukemia we have followed the immunophenotype and configuration of Ig- and TCR genes during the course of different chemotherapy regimens directed first against the myeloid and later against the lymphoid components of the disease.
|
1312481 |
1992 |
TRBV20OR9-2
|
0.100 |
Biomarker
|
disease |
BEFREE |
In 3 of 15 patients, the leukemia and histiocytic lesion shared immunoglobulin H or monoclonal TCR gene rearrangements and, in 4 of 15 patients, clonal identity was documented by fluorescence in situ hybridization.
|
19642834 |
2010 |
TRBV20OR9-2
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our cytogenetic analysis of one such cell line, SUP-T3, demonstrates that the breakpoints on chromosomes 7 and 9 lie within bands q36 and q34, respectively, corresponding to the location of the gene encoding the beta chain of the T-cell receptor, TCRB, and the gene homologous to the transforming gene of the Abelson murine leukemia virus, ABL.
|
3025859 |
1987 |
TRBV20OR9-2
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
One is based on the detection of aberrant expression of leukemia specific antigens by flow cytometry and the other one uses the specific rearrangements of the TCR or Ig genes, which can be detected by quantitative PCR in the DNA of leukemic cells.
|
23233572 |
2012 |